Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Other Non-Current Assets (2019 - 2025)

Benitec Biopharma has reported Other Non-Current Assets over the past 7 years, most recently at $11000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $11000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $11000.0 (changed N/A YoY), and the annual figure for FY2025 was $55000.0, up 120.0%.
  • Other Non-Current Assets reached $11000.0 in Q4 2025 per BNTC's latest filing, down from $20000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $567000.0 in Q3 2023 and bottomed at $9000.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $25000.0 (2021), compared with a mean of $133105.3.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 5444.44% in 2021 before it tumbled 94.99% in 2022.
  • Over 5 years, Other Non-Current Assets stood at $499000.0 in 2021, then crashed by 94.99% to $25000.0 in 2022, then surged by 1644.0% to $436000.0 in 2023, then crashed by 87.16% to $56000.0 in 2024, then crashed by 80.36% to $11000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for BNTC at $11000.0 in Q4 2025, $20000.0 in Q3 2025, and $55000.0 in Q2 2025.